We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
Drugs and drug candidates discussed: Fovista, lampalizumab, Lucentis (ranibizumab), Eylea (aflibercept), Avastin (bevacizumab), and Ozurdex (dexamethasone-eluting implant).
Disease Group Covered: Ophthalmology

Figure: Number of patient eyes treated for WET AMD (in the last year)